Education
About Us
Working with TipRanks
Follow Us
MicroTech Medical (Hangzhou) Co., Ltd. Class H (HK:2235)
:2235
Top Page
MicroTech Medical (Hangzhou) Co., Ltd. Class H
(2235)
Select Model
Select Model
Rating:55Neutral
Price Target:
HK$8.50
▲(5.72% Upside)
MicroTech Medical's overall stock score is primarily influenced by its strong revenue growth and positive technical indicators, suggesting potential for future appreciation. However, significant challenges in profitability and cash flow management, along with a negative P/E ratio, weigh down the score.
MicroTech Medical (Hangzhou) Co., Ltd. Class H (2235) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$3.52B
Dividend YieldN/A
Average Volume (3M)418.77K
Price to Earnings (P/E)―
Beta (1Y)0.35
Revenue Growth49.86%
EPS Growth80.35%
CountryHK
Employees678
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding169,175,840
10 Day Avg. Volume231,160
30 Day Avg. Volume418,773
Financial Highlights & Ratios
PEG Ratio0.79
Price to Book (P/B)1.22
Price to Sales (P/S)6.98
P/FCF Ratio-11.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$6.60Price Target Upside-17.91% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering1
MicroTech Medical (Hangzhou) Co., Ltd. Class H Business Overview & Revenue Model
Company DescriptionMicroTech Medical (Hangzhou) Co., Ltd. engages in the research and development, manufacture, and commercialization of diabetes management medical devices and consumables in the People's Republic of China and internationally. Its products include Equil Patch insulin pump systems, AiDEX continuous glucose monitoring systems, POCT analyzer systems, blood glucose monitoring systems, and closed-loop artificial pancreas. The company is also involved in engineering and technology research experimentation and development activities. MicroTech Medical (Hangzhou) Co., Ltd. was incorporated in 2011 and is headquartered in Hangzhou, the People's Republic of China.
How the Company Makes MoneyMicroTech Medical generates revenue primarily through the sale of its medical devices and technology solutions. Key revenue streams include direct sales of insulin delivery systems, blood glucose monitoring devices, and related accessories to hospitals, clinics, and pharmacies. The company also engages in partnerships with healthcare providers and organizations to supply its products, which can further enhance sales volume. Additionally, MicroTech Medical may earn income from research and development agreements, as well as licensing its technology to other medical device manufacturers. Strategic collaborations with healthcare institutions and participation in medical conferences help the company to increase brand visibility and expand its customer base, contributing to overall revenue growth.
MicroTech Medical (Hangzhou) Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
60
Neutral
Cash Flow
40
Negative
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 345.62M | 248.35M | 173.54M | 151.40M | 75.28M |
| Gross Profit | 182.85M | 123.22M | 79.66M | 70.88M | 36.54M |
| EBITDA | -121.38M | -184.12M | -110.19M | -39.80M | -141.52M |
| Net Income | -63.12M | -125.02M | -35.04M | -48.18M | -121.01M |
Balance Sheet | |||||
| Total Assets | 2.15B | 2.16B | 2.29B | 2.33B | 777.27M |
| Cash, Cash Equivalents and Short-Term Investments | 1.71B | 1.89B | 2.05B | 2.15B | 654.99M |
| Total Debt | 4.20M | 5.06M | 717.00K | 255.00K | 126.00K |
| Total Liabilities | 171.72M | 97.70M | 82.06M | 82.48M | 48.76M |
| Stockholders Equity | 1.97B | 2.06B | 2.21B | 2.25B | 728.52M |
Cash Flow | |||||
| Free Cash Flow | -203.88M | -181.69M | -137.45M | -62.94M | -35.26M |
| Operating Cash Flow | -120.65M | -153.00M | -107.67M | -44.22M | -9.57M |
| Investing Cash Flow | 121.16M | -540.70M | -965.58M | 97.69M | -1.22M |
| Financing Cash Flow | -33.15M | -23.46M | -20.57M | 1.57B | 511.28M |
MicroTech Medical (Hangzhou) Co., Ltd. Class H Technical Analysis
Positive
8.04
Price Trends
7.75
Positive
6.98
Positive
6.30
Positive
Market Momentum
0.12
Positive
56.84
Neutral
91.74
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2235, the sentiment is Positive. The current price of 8.04 is below the 20-day moving average (MA) of 8.18, above the 50-day MA of 7.75, and above the 200-day MA of 6.30, indicating a bullish trend. The MACD of 0.12 indicates Positive momentum. The RSI at 56.84 is Neutral, neither overbought nor oversold. The STOCH value of 91.74 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2235.
MicroTech Medical (Hangzhou) Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | HK$7.53B | 34.03 | 11.79% | 1.28% | -5.18% | -9.69% | |
55 Neutral | HK$3.52B | ― | -1.39% | ― | 49.86% | 80.35% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$3.72B | 659.09 | 0.22% | ― | -4.38% | ― | |
50 Neutral | HK$1.48B | ― | -26.80% | ― | -8.56% | -14.84% |
* Healthcare Sector Average
HK:2235
MicroTech Medical (Hangzhou) Co., Ltd. Class H
7.88
3.66
86.73%
DE:4WO
Peijia Medical Ltd.
0.71
0.27
61.36%
DE:7W3
Acotec Scientific Holdings Limited
1.49
0.63
73.26%
HK:2160
MicroPort CardioFlow Medtech Corp.
1.45
0.64
79.01%
HK:2172
MicroPort NeuroTech Limited
12.49
3.16
33.87%
HK:2500
Venus Medtech (Hangzhou), Inc. Class H
3.22
-2.40
-42.70%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.